Brief: Biogen, Xbrane Announce Commercialization And License Agreement For Proposed Biosimilar Referencing Cimzia
07/02/2022 21:54
Feb 7 (Reuters) - Biogen Inc BIIB.O :
* BIOGEN AND XBRANE ANNOUNCE COMMERCIALIZATION AND LICENSE
AGREEMENT FOR PROPOSED BIOSIMILAR REFERENCING CIMZIA®
(CERTOLIZUMAB PEGOL) WITH THE POTENTIAL TO TREAT RHEUMATOID
ARTHRITIS
* BIOGEN INC - WILL MAKE AN UPFRONT PAYMENT OF $8 MILLION TO
XBRANE
* BIOGEN INC - SHOULD CERTAIN MILESTONES BE ACHIEVED, XBRANE
WILL
BE ELIGIBLE TO RECEIVE UP TO $80 MILLION IN POTENTIAL MILESTONE
PAYMENTS
* BIOGEN INC - XBRANE IS ALSO ELIGIBLE TO RECEIVE TIERED
ROYALTIES
* BIOGEN INC - XBRANE WILL BE RESPONSIBLE FOR COMPLETION OF
PRE-CLINICAL DEVELOPMENT OF XCIMZANE
* BIOGEN INC - BIOGEN WILL BE RESPONSIBLE FOR ALL REMAINING
DEVELOPMENT ACTIVITIES AND COSTS REQUIRED TO ACHIEVE MARKETING
AUTHORIZATION FOR XCIMZANE
Source text for Eikon: ID:nGNX2Lg0Js
Further company coverage: BIIB.O
((Reuters.Briefs@thomsonreuters.com;))